JENNIFER BECHER: Open Payments
NPI 1346540192 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,467 in 84 payments from 12 companies in 2025. Trend: 2023 $1,514 · 2024 $2,077 · 2025 $1,467
Food & beverage: $1,382Education: $85
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $354 |
| Janssen Biotech, Inc. | 16 | $334 |
| Madrigal Pharmaceuticals | 22 | $317 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $140 |
| Gilead Sciences, Inc. | 4 | $117 |
| Amgen Inc. | 3 | $52 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $42 |
| Regeneron Healthcare Solutions, Inc. | 2 | $39 |
| Intercept Pharmaceuticals, Inc. | 2 | $29 |
| IRONWOOD PHARMACEUTICALS, INC | 1 | $23 |
Products named: TREMFYA, REZDIFFRA, RINVOQ, LINZESS, ENTYVIO, SKYRIZI, UPLIZNA, XIFAXAN.
Industry payments across NE — which companies pay providers there.
